|
| View:
Latest News | Top Stories |
|
| 1.
|
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution
-
PR Newswire
-
Fri Nov 6
Caraco Pharmaceutical Laboratories, Ltd. has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US Food and Drug Administration for Sun Pharma's Abbreviated New Drug Application for generic Acular® ophthalmic solution on the first day following patent expiration.
|
|
| 2.
|
Specialty Pharma Stock Picks From David Amsellem Of Piper Jaffray
-
Wall Street Transcript
-
Fri Nov 6
67 WALL STREET, New York - November 6, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
|
|
| 3.
|
Par Pharmaceutical Reports EPS of $0.76 for Third Quarter 2009
-
PR Newswire
-
Fri Nov 6
Par Pharmaceutical Companies, Inc. today reported results for the third quarter ended October 3, 2009.
|
|
| 4.
|
Pro-Pharmaceuticals Closes $310,000 Tranche; Brings Total to $4.1 Million of $6.0 Million Private Placement
-
Business Wire
-
Wed Nov 4
NEWTON, Mass.----Pro-Pharmaceuticals, Inc. , today announced that it has closed a $310,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants.
|
|
| 5.
|
Watson Reports Third Quarter 2009 GAAP EPS of $0.55; Adjusted EPS of $0.66
-
PR Newswire
-
Wed Nov 4
Watson Pharmaceuticals, Inc. today reported net income of $63.0 million, or $0.55 per diluted share for the third quarter ended September 30, 2009. Excluding special items as detailed in the reconciliation table below, adjusted net income for the third quarter was $76.1 million, or $0.66 per diluted share, an increase of $22.1 million or 41 percent over the adjusted net income for the third quarter ended September 30, 2008.
|
|
| 6.
|
Hi-Tech Pharmacal to Present at the 20th Annual Oppenheimer Healthcare Conference
-
Business Wire
-
Fri Oct 30
AMITYVILLE, N.Y.----Hi-Tech Pharmacal Co., Inc. today announced that it is scheduled to make an investor presentation at the 20th Annual Oppenheimer Healthcare Conference. David Seltzer, President and Chief Executive Officer, will deliver the Company's presentation on Tuesday, November 3, 2009, at 3:55 p.m.
|
|
| 7.
|
Mylan reports 3Q loss on revenue drop, charge
-
AP
-
Thu Oct 29
Generic drugmaker Mylan Inc. said Thursday it posted a loss during the third quarter on a mix of lower revenue and costs for a legal settlement.
|
|
| 8.
|
/C O R R E C T I O N -- Caraco Pharmaceutical Laboratories, Ltd./
-
PR Newswire
-
Tue Oct 27
Oct-2009 by Caraco Pharmaceutical Laboratories, Ltd. over PR Newswire, we are advised by the company that the Statements of Income table included certain figures that have since been corrected.
|
|
| 9.
|
Helicos BioSciences climbs on publication report
-
AP
-
Thu Sep 24
Helicos BioSciences Corp. said Thursday its True Single Molecule Sequencing technology was used to directly sequence individual RNA molecules in a recent study.
|
|
| 10.
|
FDA Accepts Drug Application for Miconazole Lauriad(R) to Treat Oropharyngeal Candidiasis
-
PR Newswire
-
Wed Aug 19
Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. , today announced that the U.S. Food and Drug Administration has accepted the new drug application for miconazole Lauriad mucoadhesive buccal tablets to treat oropharyngeal candidiasis .
|
|
